CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The project aims to develop a targeted metabolomics test platform that integrates in vitro cell assays with user-friendly test kits. This innovation seeks to improve drug testing accuracy and reduce development costs in the healthcare sector.
The healthcare industry is experiencing unprecedented rates of drug failure, long development times and high costs - because current lab tests and disease models (in vitro) don’t adequately predict drug effect in the patient (in vivo).
To address this “Challenge”, three leading EU SMEs;
Luxcel Biosciences Ltd, Axiogenesis AG and BMG Labtech GmbH, are partnering to bring to market, a fully integrated targeted metabolomics Test Platform, comprising physiologically relevant in vitro cell assays and…
LUXCEL BIOSCIENCES LTD
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Germany, ORTENBERG
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Netherlands, Leiden
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: No
Germany, KOLN
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
United Kingdom, Oxford
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
